North East Pharmaceutical Manufacturing Showcase – leading the way in flow chemistry & continuous processing

About this Session

In this session, NEPIC will bring together some key players from the North East pharmaceutical cluster to discuss the strengths of pharma manufacturing within the region. We will be joined by NEPIC member companies to discuss their journeys within the sector, as well as key challenges, opportunities, technology trends and synergies with the chemical sector. A particular focus will be placed on the role of continuous processing, as this is one of the key areas of innovation within the pharma manufacturing space. This will be a great opportunity to find out more about a regional sector that contributes a third of the UK’s pharmaceutical GDP.

Session Host: Ryan Siddall, Head of Technical, North East Process Industry Cluster (NEPIC)

Panellists/Presentation Title:

James Rogers, Site Head, Sterling Pharma Solutions
The Role of flow in environmental sustainability
_________________________________________________

Will Reynolds, Flow Chemistry Development Chemist, Sterling Pharma Solutions
The Role of flow in environmental sustainability
_________________________________________________

Stephen Byard, Principal Research Fellow, Science & Technology, Candidate Development, Quotient Sciences
Translational Pharmaceutics®: Accelerating Synthesis to Clinic and Beyond
_________________________________________________

Christine Gardner, Inspection and Packaging Technical Lead, GSK
GSK Barnard Castle the future is bright…..
_________________________________________________

Dr. Charles Heiss, Associate Director – Fujifilm Diosynth Biotechnologies
FUJIFILM Diosynth Biotechnologies capabilities and the MaruX^TM continuous biomanufacturing platform

Continuous manufacturing provides a solution for uncertainty in capacity as drug candidates progress through clinical development to commercial supply. However, adoption has been slow due to technical and operational challenges associated with managing large liquid volumes, integration of unit operations, and environmental and process controls. We have executed the successful production of a monoclonal antibody using a 500 L scale connected process with a single-use flow path in a non-GMP pilot facility, which is a forerunner to the construction of flexible continuous GMP manufacturing facilities.